Beyond the signal sequence: Protein routing in health and disease

Endocrine Reviews

Volumn 26, Issue 4, 2005, Pages 479-503

  Castro Fernández, Cecilia ^a,c   Maya Núñez, Guadalupe ^a,c   Conn, P Michael ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIOXIDANT; ASCORBIC ACID; CASTANOSPERMINE; CHAPERONE; ELLIPTICINE; ENZYME; G PROTEIN COUPLED RECEPTOR; GLYCEROL; HORMONE; ION CHANNEL; LIXIVAPTAN; MEPACRINE; MINOCYCLINE; MONOCLONAL ANTIBODY; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PEPTIDOMIMETIC AGENT; POLYPEPTIDE; PORPHYRIN; RECEPTOR; RETINOL; TETRACYCLINE; UBIDECARENONE; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CATARACT; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CELL STRUCTURE; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; MOLECULAR DYNAMICS; NEUROPATHY; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; DISEASE; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HUMANS; MITOCHONDRIA; MOLECULAR CHAPERONES; MUTATION; NERVOUS SYSTEM DISEASES; PROTEIN CONFORMATION; PROTEIN SORTING SIGNALS; PROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 21644476127     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2004-0010     Document Type: Review

References (264)

1. Dobson CM 2003 Protein folding and misfolding. Nature 426:884-890
2. Kopito RR 2000 Aggregosomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524-530
3. Kostova Z, Wolf DH 2003 For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. EMBO J 22:2309-2317
4. Haigh NG, Johnson AE 2002 Protein sorting at the membrane of endoplasmic reticulum. In: Dalbey RE, Von Heijne G, eds. Protein targeting, transport and translocation. London: Academic Press; 74-106
5. Klausner RD, Sitia R 1990 Protein degradation in the endoplasmic reticulum. Cell 62:611-614
6. Chevet E, Cameron PH, Pelletier MF, Thomas DY, Bergeron JJM 2001 The endoplasmic reticulum: integration of protein folding, quality control, signaling and degradation. Curr Opin Struct Biol 11:120-124
7. Ellgaard L, Helenius A 2003 Quality control in the endoplasmic reticulum. Nat Rev 4:181-191
8. Sitia R, Braakman I 2003 Quality control in the endoplasmic reticulum protein factory. Nature 426:891-894
9. Fra AM, Fagioli C, Finazzi D, Sitia R, Alberini CM 1993 Quality control of ER synthesized proteins: an exposed thiol group as a three-way switch mediating assembly, retention and degradation. EMBO J 12:4755-4761
10. Helenius A, Trombetta ES, Hebert DN, Simons JF 1997 Calnexin, calreticulin and the folding of glycoproteins. Trends Cell Biol 7:193-200
11. Hellman R, Vanhove M, Lejeune A, Stevens FJ, Hedershot LM 1999 The in vivo association of BiP with newly synthesized proteins is dependent on the rate and stability of folding and not simply on the presence of sequences that can bind to BiP. J Cell Biol 144:21-30
12. Ellgaard L, Molinari M, Helenius A 1999 Setting the standards: quality control in the secretory pathway. Science 286:1882-1888
13. Oda Y, Hosokawa N, Wada I, Nagata K 2003 EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. Science 299:1394-1397
14. Molinari M, Calanca V, Galli C, Lucca P, Paganetti P 2003 Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. Science 299:1397-1400
15. Hammond C, Helenius A 1995 Quality control in the secretory pathway. Curr Opin Cell Biol 7:523-529
16. Cabral CM, Liu Y, Sifers RN 2001 Dissecting glycoprotein quality control in the secretory pathway. Trends Biochem Sci 26:619-624
17. Bonifacino JS, Klausner RD 1994 Degradation of proteins retained in the endoplasmic reticulum. Modern Cell Biol 15:137-159
18. Fewell SW, Travers KJ, Weissman JS, Brodsky JL 2001 The action of molecular chaperones in the early secretory pathway. Annu Rev Genet 35:149-191
19. Coux O, Tanaka K, Goldenberg AL 1996 Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801-847
20. Hershko A, Ciechanover A 1998 The ubiquitin system. Annu Rev Biochem 67:425-479
21. Sherman MY, Goldberg AL 2001 Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15-32
22. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D 2000 A gated channel into the proteasome core particle. Nat Struct Biol 7:1062-1067
23. Bernaroudj N, Zwickl P, Seemüller E, Baumester W, Goldberg AL 2003 ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol Cell 11:69-78
24. Wickner S, Maurizi MR, Gottesman S 1999 Posttranslational quality control: folding, refolding, and degrading proteins. Science 286:1888-1893
25. Rothman JE, Wieland FT 1996 Protein sorting by transport vesicles. Science 272:227-234
26. Schekman R, Orci L 1996 Coat proteins and vesicle budding. Science 271:1526-1533
27. Kuehn MJ, Hermann JM, Schekman R 1998 COPII-cargo interactions direct protein sorting into ER-derived transport vesicles. Nature 391:187-190
28. Taxis C, Vogel F, Wolf DH 2002 ER-Golgi traffic is a prerequisite for efficient ER degradation. Mol Biol Cell 13:1806-1818
29. Mezzacasa A, Helenius A 2002 The transitorial ER defines a boundary for quality control in the secretion of tsO45 VSV glycoprotein. Traffic 3:833-849
30. Hammond C, Helenius A 1994 Quality control in the secretory pathway: retention of a misfolded viral membrane glycoprotein involves cycling between the ER, intermediate compartment, and Golgi apparatus. J Cell Biol 126:41-52
31. Arvan P, Zhao X, Ramos-Castaneda J, Chang A 2002 Secretory pathway quality control operating in Golgi, plasmalemmal, and endosomal systems. Traffic 3:771-780
32. VanSlyke JK, Deschenes SM, Musil LS 2000 Intracellular transport, assembly, and degradation of wild-type and disease-linked mutant gap junction proteins. Mol Biol Cell 11:1933-1946
33. Caldwell SR, Hill KJ, Cooper AA 2001 Degradation of endoplasmic reticulum (ER) quality control substrates requires transport between the ER and Golgi. J Biol Chem 276:23296-23303
34. Vashist S, Kim W, Belden WJ, Spear ED, Barlowe D, Ng DT 2001 Distinct retrieval and retention mechanisms that are required for the quality control of endoplasmic reticulum protein folding. J Cell Biol 155:355-368
35. Zuber C, Spiro MJ, Guhl B, Spiro RG, Roth J 2000 Golgi apparatus immunolocalization of endomannosidase suggests post-endoplasmic reticulum glucose trimming. Implications for quality control. Mol Biol Cell 11:4227-4240
36. Zuber C, Fan JY, Guhl B, Parodi A, Fessler JH, Parker C, Roth J 2001 Immunolocalization of UDP-glucose:glycoprotein glucosyltransferase indicates involvement of pre-Golgi intermediates in protein quality control. Proc Natl Acad Sci USA 98:10710-10715
37. Roth J, Ziak M, Zuber C 2003 The role of glucosidase II and endomannosidase in glucose trimming of asparagine-linked oligosaccharides. Biochimie 85:287-294
38. Busca R, Martinez M, Vilella E, Pognonoec P, Deeb S, Auwerx J, Reina M, Vilaro S 1996 The mutation Gly142Glu in human lipoprotein lipase produces a missorted protein that is diverted to lysosomes. J Biol Chem 271:2139-2146
39. Millar CA, Meerloo T, Martin S, Hickson GRX, Shimwell NJ, Wakelam MJO, James DE, Gould GW 2000 Adipsin and the glucose transporter GLUT4 traffic to the cell surface via independent pathways in adipocytes. Traffic 1:141-151
40. Turner M, Arvan P 2000 Protein traffic from the secretory pathway to the endosomal system in pancreatic β-cells. J Biol Chem 275:14025-14030
41. Harsay F, Schekman R 2002 A subset of yeast vacuolar protein sorting mutants is blocked in one branch of the exocytic pathway. J Cell Biol 156:271-286
42. Munro S 1995 An investigation of the role of transmembrane domains in Golgi protein retention. EMBO J 14:4695-4705
43. Wolins N, Bosshart H, Kuster H, Bonifacino JS 1997 Aggregation as a determinant of protein fate in post-Golgi compartments: role of the luminal domain of furin in lysosomal targeting. J Cell Biol 139:1735-1745
44. Stock D, Gibbons C, Arechaga I. Leslie AG, Walker JE 2000 The rotary mechanism of ATP synthase. Curr Opin Struct Biol 10:672-679.
45. Eckert A, Keil U, Marques A, Bonert A, Frey C, Schüssel, Müller WE 2003 Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 66:1627-1634
46. Langer T, Neupert W 1996 Regulated protein degradation in mitochondria. Experientia 52:1069-1076
47. Martin J 1997 Molecular chaperones and mitochondrial protein folding. J Bioenerg Biomembr 29:35-43
48. Koehler CM 2000 Protein translocation pathways of the mitochondrion. FEBS Lett 476:27-31
49. Voos W, Rörrgers K 2002 Molecular chaperones as essential mediators of mitochondrial biogenesis. Biochim Biophys Acta 1592:51-62
50. Bross P, Corydon TJ, Andersen BS, Jørgensen MM, Bolund L, Gregersen N 1999 Protein misfolding and degradation in genetic diseases. Hum Mutat 14:186-198
51. Bukau B, Horwich AL 1998 The Hsp70 and Hsp60 chaperone machines. Cell 92:351-366
52. Hartl FU, Hayer-Hartl M 2002 Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852-1858
53. Stirling PC, Lundin VF, Leroux MR 2003 Getting a grip on nonnative proteins. EMBO Rep 4:565-570
54. Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C 2003 Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun 304:505-512
55. Feldman DE, Frydman J 2000 Protein folding in vivo: the importance of molecular chaperones. Curr Opin Struct Biol 10:26-33
56. Molinari M, Helenius A 2000 Chaperone selection during glycoprotein translocation into the endoplasmic reticulum. Science 288:331-333
57. Frydman J, Hohfeld J 1997 Chaperones get in touch: the Hip-Hop connection. Trends Biochem Sci 22:87-92
58. Kelley WL 1998 The J-domain family and the recruitment of chaperone power. Trends Biochem Sci 23:222-227
59. Parsell D, Kowal A, Singer M, Lindquist S 1994 Protein dissaggregation mediate by heat shock protein Hsp104. Nature 372:475-478
60. Patino MM, Liu JJ, Gloover JR, Lindquist S 1996 Support of the prion hypothesis for inheritance of a phenotypic trait in yeast. Science 273:622-626
61. Glover JR, Lindquist S 1998 Hsp104, Hsp70 and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 94:73-82
62. Parodi AJ 2000 Protein glycosylation and its role in protein folding. Annu Rev Biochem 69:611-614
63. Ou W, Cameron P, Thomas D, Bergeron J 1993 Association of folding intermediate of glycoproteins with calnexin during protein maturation. Nature 364:771-776
64. McCracken AA, Brodsky JC 1996 Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J Cell Biol 132:291-298
65. 2 oligosaccharide as an initial step in recognizing unfolded glycoproteins. J Biol Chem 270:4697-4704
66. Liu Y, Choudhury P, Cabral CM, Siters RN 1999 Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glycoprotein for degradation by the proteasome. J Biol Chem 274:5861-5867
67. Molinari M, Helenius A 1999 Glycoproteins from mixed disulfides with oxidoreductases during folding in living cells. Nature 402:90-93
68. Janovick JA, Maya-Núñez G, Conn PM 2002 Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87:3255-3262
69. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG, Conn PM 2003 Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther 305:608-614
70. Tan CM, Brady AE, Nickols HH, Wang Q, Limbird LE 2004 Membrane trafficking of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 44:559-609
71. Conn PM, Leanos-Miranda A, Janovick JA 2002 Protein origami: therapeutic rescue of misfolded gene products. Mol Interv 2:308-316
72. Maya-Núñez G, Janovick JA, Ulloa-Aguirre A, Söderlund D, Conn PM, Méndez JP 2002 Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E90K) GnRH receptor function by a deletion at a distant site. J Clin Endocrinol Metab 87:2144-2149
73. Leaños-Miranda A, Janovick JA, Conn PM 2002 Receptormisrouting: an unexpectedly prevalent and rescuable etiology in GnRHR-mediated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 87:4825-4828
74. Ulloa-Aguirre A, Janovick JA, Leaños-Miranda A, Conn PM 2003 Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: the case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance. Expert Opin Ther Targets 7:175-185
75. Leaños-Miranda A, Ulloa-Aguirre A, Ji TH, Janovick JA, Conn PM 2003 Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans. J Clin Endocrinol Metab 88:3360-3367
76. Brothers SP, Cornea A, Janovick JA, Conn PM 2004 Human 'loss-of-function' GnRH receptor mutants retain wild type receptor in the endoplasmic reticulum: molecular basis of the dominantnegative effect. Mol Endocrinol 18:1787-1797
77. Janovick, J, Ulloa-Aguirre A, Conn PM 2003 Evolved regulation of gonadotropin releasing hormone receptor plasma membrane expression. Endocrine 22:317-328
78. Söderlund D, Canto P, De la Chesnaye E, Ulloa-Aguirre A, Méndez JP 2001 A novel homozygous mutation in the second transmembrane domain of the gonadotropin releasing hormone receptor gene. Clin Endocrinol (Oxf) 54:493-498
79. Brothers SP, Janovick JA, Conn PM 2003 Unexpected effects of epitope and chimeric tags on gonadotropin-releasing hormone receptors: implications for understanding the molecular etiology of hypogonadotropic hypogonadism. J Clin Endocrinol Metab 88:6107-6112
80. Noorwez SM, Kuksa V, Imanishi Y, Zhu L, Filipek S, Palczewski K, Kaushal S 2003 Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem 278:14442-14450
81. Noorwez SM, Malhotra R, McDowell JH, Smith KA, Krebs MP, Kaushal S 2004 Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem 279:16278-16284
82. Colley NJ, Cassill JA, Baker EK, Zuker CS 1995 Defective intracellular transport is the molecular basis of rhodopsin-dependent dominant retinal degeneration. Proc Natl Acad Sci USA 92:3070-3074
83. Tamarappoo BK, Verkman AS 1998 Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 101:2257-2267
84. Kamsteeg EJ, Wormhoudt TAM, Rijss JPL, van Os CH, Deen PMT 1999 An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J 18:2394-2400
85. Kamsteeg EJ, Bichet DG, Konings IBM, Nivet H, Lonergan M, Arthus MF, van Os CH, Deen PMT 2003 Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. J Cell Biol 163:1099-1109
86. Morello JP, Bichet DG 2001 Nephrogenic diabetes insipidus. Annu Rev Physiol 63:607-630
87. Hirano K, Zuber C, Roth J, Ziak M 2003 The proteasome is involved in the degradation of different aquaporin-2 mutants causing nephrogenic diabetes insipidus. Am J Pathol 163:111-120
88. Petäjä-Repo UE, Hogue M, Laperrière A, Walker P, Bouvier M 2000 Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human δ opioid receptor. J Biol Chem 275:13727-13736
89. Bai M 2004 Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 16:175-186
90. Conn PM, Rogers DC, Stewart JM, Niedel J, Sheffield T 1982 Conversion of a gonadotropin-releasing hormone antagonist to an agonist. Nature 296:653-655
91. Robbins MJ, Ciruela F, Rhodes A, McIllhinney RA 1999 Characterization of the dimerization of metabotropic glutamate receptors using an N-terminal truncation of mGluR1α. J Neurochem 72:2539-2547
92. Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C, Bouvier M 2003 Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 17:677-691
93. Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, Albar JP, Martinez AC, Mellado M 1999 The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 96:3628-3633
94. Vila-Coro AJ, Mellado M, Martin de Ana A, Lucas P, del Real G, Marinez AC, Rodriguez-Frade JM 2000 HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci USA 97:3388-3393
95. Cornea A, Janovick JA, Maya-Núñez G, Conn PM 2001 Gonadotropin-releasing hormone receptor microaggregation. Rate monitored by fluorescence resonance energy transfer. J Biol Chem 276:2153-2158
96. Zhu X, Wess J 1998 Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry 37:15773-15784
97. Lee SP, O'Dowd BF, Ng GY, Varghese G, Akil H, Mansour A, Nguyen T, George SR 2000 Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. Mol Pharmacol 58:120-128
98. Kaykas A, Yang-Snyder J, Heroux M, Shah KV, Bouvier M, Moon RT 2004 Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nat Cell Biol 6:52-58
99. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin M, Dai M, Yao WJ, Johnson M, Gunwaldsen C, Huang LY, Tang C, Shen O, Salon JA, Morse K, Laz T, Smith KE, Nagarathnam D, Noble SA, Branchek TA, Gerald C 1998 GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396:674 - 679
100. Galvez T, Duthery B, Kniazeff J, Blahos J, Rovelli G, Bettler B, Prezeau L, Pin JP 2001 Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 202152-2159
101. Pagano A, Rovelli G, Mosbacher J, Lohmann T, Duthey B, Stauffer D, Ristig D, Schuler V, Meigel I, Lampert C, Stein T, Prezeau L, Blahos J, Pin J, Froestl W, Kuhn R, Heid J, Kaupmann K, Bettler B 2001 C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors. J Neurosci 21:1189-1202
102. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH, Jochemsen AG 2003 Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23:4929-4938
103. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR 2000 Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19:370-378
104. Peng Y, Li C, Chen L, Sebti S, Chen J 2003 Rescue of mutant p53 transcription function by ellipticine. Oncogene 22:4478-4487
105. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR 1999 Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci USA 90:8586-8590
106. Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G 2002 Restoration of the tumor suppressor function to mutant p53 by a lowmolecular weight compound. Nat Med 8:282-288
107. Pfeiffer R, Loffing J, Rossier G, Bauch C, Meier C, Eggermann T, Loffing-Cueni D, Kühn LC, Verrey F 1999 Luminal heterodimeric amino acid transporter defective in cystinuria. Mol Biol Cell 10:4135-4147
108. Chillarón J, Estévez R, Samarzija I, Waldegger S, Testar X, Lang F, Zorzano A, Busch A, Palacín M 1997 An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K. J Biol Chem 272:9543-9549
109. 0,+ AT. Biochem J 377:665-674
110. Rutishauser J, Spiess M 2002 Endoplasmic reticulum storage diseases. Swiss Med Wkly 132:211-222
111. Springsteel MF, Galietta LJV, Ma T, By K, Berger GO, Yang H, Dicus CW, Choung W, Quan C, Shelat AA, Guy RK, Verkman AS, Kurth MJ, Nantz MH 2003 Benzaflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioor Med Chem 11:4113-4120
112. Randell Brown C, Hong-Brown LQ, Welch WJ 1997 Strategies for correcting the ΔF508 CFTR protein-folding defect. J Bioenerg Biomembr 29:491-502
113. Gilbert A, Jadot M, Leontieva E, Wattiaux-De Coninck S, Wattiaux R 1998 DF508 CFTR localizes in the endoplasmic reticulum-Golgi intermediate compartment in cystic fibrosis cells. Exp Cell Res 242:144-152
114. Qu BH, Strickland E, Thomas PJ 1997 Cystic fibrosis: a disease of altered protein folding. J Bioenerg Biomembr 29:483-490
115. Okiyoneda T, Harada K, Takeya M, Yamahira K, Wada I, Shuto T, Suico MA, Hashimoto I, Kai H 2004 ΔF508 CFTR pool in the endoplasmic reticulum is increased by calnexin overexpression. Mol Biol Cell 15:563-574
116. Zeitllin PL 1999 Novel pharmacologic therapies for cystic fibrosis. J Clin Invest 103:447-452
117. Gitelman HJ, Graham JB, Welt LG 1966 A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79:221-235
118. Bettinelli A, Vezzoli G, Colussi G, Bianchetti MG, Sereni F, Casari G 1998 Genotype-phenotype correlations in normotensive patients with primary renal tubular hypokalemic metabolic alkalosis. J Nephrol 11:61-69
119. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB 2001 Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 59:710-717
120. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG 1999 Genetic disorder of renal electrolyte transport. N Engl J Med 340:1177-1187
121. De Jong JC, Van Der Vliet WA, Van Den Heuvel LPWJ, Willems PHGM, Knoers NVAM, Bindels RJM 2002 Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman's syndrome. J Am Soc Nephrol 13:1442-1448
122. Gamba G, Miyanoshita A, Lombardi M, Lytton J, Lee WS, Hediger MA, Hebert SC 1994 Molecular cloning, primary structure, and characterization of two members of the mammalian electroneutral sodium-(potassium)-chloride cotransporter family expressed in kidney. J Biol Chem 269:17713-17722
123. Velazquez H, Náray-Fejes-Tóth A, Silva T, Andújar E, Reilly RF, Desir V, Ellison DH 1998 The distal convoluted tubule of the rabbit coexpresses NaCl cotransporter and 11β-hydroxysteroid dehydrogenase. Kidney Int 54:464-472
124. Wyse BD, Ali N, Ellison DH 2002 Interaction with grp58 increases activity of the thiazide-sensitive Na-Cl cotransporter. Am J Physiol 282:F424-F430
125. Giannetti AM, Björkman PJ 2004 HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface. J Biol Chem 279:25866-25875
126. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN, Schatzman RC, Britton RS, Bacon BR, Sly WS 1997 Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with β2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 94:12384-12389
127. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis ML, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland EE, Meyer NC, Mintier GA, Moeller NN, Moore T, Morikang E, Prass LE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK 1996 A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399-408
128. Bodmer JG, Parham P, Albert ED, Marsh SGE 1997 Putting a hold on "HLA-H'. The WHO Nomenclature Committee for Factors of the HLA System. Nat Genet 15:234-235
129. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC 1998 The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 95:1472-1477
130. Björkman PJ, Parham P 1990 Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59:253-288
131. Miyazaki J, Appella E, Ozato K 1986 Intracellular transport blockade caused by disruption of the disulfide bridge in the third external domain of major histocompatibility complex class I antigen. Proc Natl Acad Sci USA 83:757-761
132. Hansen TH, Myers NB, Lee DR 1988 Studies of two antigenic forms of Ld with disparate β2-microglobulin (β2m) associations suggest that β2m facilitate the folding of the α1 and α2 domains during de novo synthesis. J Immunol 140:3522-3527
133. Lebron JA, West Jr AP, Björkman PJ 1999 The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 294:239-245
134. Laham N, Rotem-Yehudar R, Shechter C, Coligan JE, Ehrlich R 2004 Transferrins receptor association with endosomal localization of soluble HFE are not sufficient for regulation of cellular iron homeostasis. J Cell Biochem 91:1130-1145
135. Williams DB, Watts TH 1995 Molecular chaperones in antigen presentation. Curr Opin Immunol 7:77-84
136. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E, Prass CE, Starnes SM, Wolff RK, Parkkila S, Sly WS, Schatzman RC 1997 The hemochromatosis founder mutation in HLA-H disrupts β2-microglobulin interaction and cell surface expression. J Biol Chem 272:14025-14028
137. Hsu VW, Yuan LC, Nuchtern JG, Lippincott-Schwartz J, Hammerling GJ, Klausner RD 1991 A recycling pathway between the endoplasmic reticulum and the Golgi apparatus for retention of unassembled MHC class I molecules. Nature 352:441-444
138. Jørgensen MM, Jensen ON, Holst HU, Hansen JJ, Corydon TJ, Bross P, Bolund L, Gregersen N 2000 Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum. J Biol Chem 275:33861-33868
139. Li Y, Lu W, Schwartz AL, Bu G 2004 Degradation of the low-density lipoprotein receptor class 2 mutants is mediated by a proteasome-dependent pathway. J Lipid Res 45:1084-1091
140. Hobbs HH, Russell DW, Brown MS, Goldstein JL 1990 The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24:133-170
141. Li Y, Lu W, Schwartz AL, Bu G 2002 Receptor-associated protein facilitates proper holding and maturation of the low-density lipoprotein receptor and its class 2 mutants. Biochemistry 41:4921-4928
142. Solomon B 2002 Anti-aggregating antibodies, a new approach towards treatment of conformation diseases. Curr Med Chem 9:1737-1749
143. Carrell RW, Lomas DA 1997 Conformational disease. Lancet 350:134-138
144. Kopito RR, Ron D 2000 Conformational disease. Nat Cell Biol 2:E207-E209
145. Martin JB 1999 Molecular basis of the neurodegenerative diseases. N Engl J Med 340:1970-1980
146. Soto C 2003 Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev 4:49-59
147. Jiménez JL, Guijarro JI, Orlova E, Zurdo J, Dobson CM, Sunde M, Saibil HR 1999 Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J 18:815-821
148. Stefani M, Dobson CM 2003 Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81:678-699
149. Dobson CM 1999 Protein misfolding, evolution and disease. Trends Biochem Sci 24:329-332
150. Dobson CM 2001 The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356:133-145
151. Lorenzo A, Yanker BA 1994 β-Amyloid neurotoxicity requires fibril formation and its inhibited by Congo red. Proc Natl Acad Sci USA 91:12243-12247
152. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M 1996 β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168-171
153. Dickson DW 1995 Correlation of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285-298
154. Csermely P 2001 Chaperone overload is a possible contributor to "civilization diseases." Trends Genet 17:701-704
155. Dobson CM 2002 Getting out of shape. Nature 418:729-730
156. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO 1989 Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262:2551-2556
157. Price DL, Borchelt DR, Sisodia SS 1993 Alzheimer disease and the prion disorders amyloid β-protein and prion protein amyloidoses. Proc Natl Acad Sci USA 90:6381-6384
158. Shastry BS 2003 Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1-7
159. Thompson AJ, Barrow CJ 2002 Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and prion diseases. Curr Med Chem 9:1751-1762
160. Hardy J, Selkoe DJ 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
161. Temussi PA, Masino L, Pastore A 2003 From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J 22:355-361
162. Lee VM, Goedert M, Trojanowski JQ 2001 Neurodegenerative tautopathies. Annu Rev Neurosci 24:1121-1159
163. McLlory SP, Vahidassr AD, Svage DA, Patterson LC, Lawson JT, Passmore AP 1999 Risk of Alzheimer's disease is associated with a very low density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet 88:140-144
164. Lichtenthaler SF, Beher D, Grim HS, Wang R, Shearman MS, Masters CL, Beyreuther K 2002 The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc Natl Acad Sci USA 99:1365-1370
165. Castaño EM, Ghiso J, Prelli F, Gorevic PD, Migheli A, Frangione B 1986 In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. Biochem Biophys Res Commun 141:782-789
166. Soto C, Castaño EM, Frangione B, Inestrosa NC1995 The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J Biol Chem 270:3063-3067
167. Hardy J, Allsop D 1991 Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383-388
168. Selkoe DJ 1996 Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem 271:18295-18298
169. Hardy J 1997 Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20:154-159
170. Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J 1991 Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706
171. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M 1998 Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to τ. Nat Neurosci 1:355-358
172. Selkoe D 2001 Presenilin, notch and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 98:11039-11041
173. Canu N, Dus L, Barbato C, Ciotti MT, Brancolini C, Rinaldi AM, Novak M, Cattaneo A, Bradbury A, Calissano P 1998 τ Cleavage and dephosphrylation in cerebellar granule neurons undergoing apoptosis. J Neurosci 18:7061-7074
174. Von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E 2000 Assembly of τ protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming β structure. Proc Natl Acad Sci USA 97:5129-5134
175. Forloni G, Terreni L, Bertani I, Fogliarino S, Invernizzi R, Assini A, Ribizzi G, Negro A, Calabrese E, Volonté MA, Mariani C, Franceschi M, Tabaton M, Bertoli A 2002 Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 23:957-976
176. Shastry BS 2001 Parkinson's disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 41:5-12
177. Tang GM, Xie XJ, Xu L, Hao YX, Lin DY, Ren DM 2002 Genetic study of apolipoprotein E gene, α-1 antichymotrypsin gene in sporadic Parkinson's disease. Am J Med Genet 114:446-449
178. Checkoway H, Powers D, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD 2002 Parkinson's disease risks associated with cigarette smoking, alcohol consumption and caffeine intake. Am J Epidemiol 155:738-752
179. Clayton DF, George JM 1998 The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21:249-254
180. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C 2000 Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci 20:6365-6373
181. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Sayito T 1995 The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475
182. Crowther RA, Daniel SE, Goedert M 2000 Characterization of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci Lett 292:128-130
183. Spillantini MG, Schidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M 1997 α-Synuclein in Lewy bodies. Nature 88:839-840
184. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M 1998 α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-6473
185. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T 1998 Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 52:879-884
186. Jenco JM, Rawlingson A, Daniels B, Morris AJ 1998 Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β synucleins. Biochemistry 37:4901-4909
187. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y, Bar-Sagi D, Morris AJ, Frohman MA 1997 Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal re-organization. Curr Biol 7:191-201
188. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R 1999 α-Synuclein binds to τ and stimulates the protein kinase A-catalyzed τ phosphorylation of serine residues 262 and 356. J Biol Chem 274:25481-25489
189. Leroy E, Boyer R, Auburguer G, Lleube B, Ulm G, Mezey E 1998 The ubiquitin pathway in Parkinson's disease. Nature 395:451-452
190. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N 1998 Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392:605-608
191. Solano SM, Miller DW, Augood SJ, Young AB, Penney JB 2000 Expression of α-synuclein, Parkin and ubiquitin carboxy-terminal hydrolase L1mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol 47:201-210
192. Margolis RL, Ross CA 2001 Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends Mol Med 7:479-482
193. Ross CA 2002 Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35:819-822
194. Browne SE, Beal MF 2004 The energetics of Huntington's disease. Neurochem Res 29:531-546
195. MacDonald ME, Vonsattel J-P, Shrinidhi J, Couropmitree NN, Cupples LA, Bird ED, Gusella JF, Myers RH 1999 Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 53:1330-1332
196. Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M 1998 Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 87:49-53
197. Chen S, Ferrone FA, Wetzel R 2002 Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci USA 99:11884-11889
198. Ross CA 1995 When less is more: pathogenesis in glutamine repeat neurodegenerative diseases. Neuron 15:493-496
199. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer GB, Mandel J-L, Trottier Y 2002 Proteases acting on mutant Huntington generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10:259-269
200. Meriin AB, Zhang XQ, He HW, Newnam GP, Chernoff YO, Sherman MY 2002 Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 157:997-1004
201. Nishitoh H, Matsuazawa D, Tobiume K, Saegusa K, Takeda K, Inoue K, Horis S, Kakizuka A, Ichijo H 2002 ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 16:1345-1355
202. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG 1996 A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921-925
203. Weissmann C, Enari M, Klöhn PC, Rossi D, Flechsig E 2002 Transmission of prions. J Infect Dis 186:S157-S165
204. Weissman C 1991 Spongiform encephalopathies. The prion's progress. Nature 349:569-571
205. Oesch B, Westaway D, Wälchli M, McKinley MP, Kent SB, Aebersold R, Barry RA, Tempst P, Teplow DB, Hood LE, Prusiner SB, Weissmann C 1985 A cellular gene encodes scrapie PrP 27-30 protein. Cell 40:735-746
206. Basler K, Oesch B, Scott M, Westaway D, Walchli M, Groth DF, McKinley MP, Prusiner SB, Weissmann C 1986 Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 46:417-428
207. Prusiner SB 1989 Scrapie prions. Annu Rev Microbiol 43:345-347
208. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL, Prusiner SB 1993 Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemstry 32:1991-2002
209. Riek R, Hornemann S, Wider G, Glockshuber R, Wüthrich K 1997 NMR characterization of the full-length recombinant murine prion protein, mPrP (23-231). FEBS Lett 413:282-288
210. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB 1993 Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962-10966
211. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS 1991 Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30:7672-7680
212. Jarrett JT, Lansbury PJ 1993 Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058
213. Prusiner SB 1991 Molecular biology of prion diseases. Science 252:1515-1522
214. Kovacs GG, Zerbi P, Voigtländer T, Strohschneider M, Trabattoni G, Hainfellner JA, Budka H 2002 The prion protein in human neurodegenerative disorders. Neurosci Lett 329:269-272
215. Chesebro B 2003 Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull 66:1-20
216. Will RG 1993 Epidemiology of Creutzfeldt-Jacob disease. Br Med Bull 49:960-970
217. Fradkin JE, Schonberger LB, Mills JL, Gunn WJ, Piper JM, Wysowski DK, Thomson R, Durako S, Brown P 1991 Creutzfeldt-Jacob disease in pituitary growth hormone recipients in the United States. JAMA 265:880-884
218. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, Mackenzie J, Estibeiro K, Green AJ, Knight RS 2000 Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 47:575-582
219. Kapaki E, Kolidireas K, Paraskevas GP, Michalopoulou M, Patsouris E 2001 Highly increased CSF τprotein and decreased β-amyloid (1- 42) in sporadic CJD: a discrimination from Alzheimer's diasese. J Neurol Neurosurg Psychiatry 71:401-403
220. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schult-Schaeffer W, Kretzschmar HA, Poser S 2002 τ protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58:192-197
221. Narang H 2002 A critical review of the nature of the spongiform encephalopathy agent: protein theory versus virus theory. Exp Biol Med 227:4-19
222. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, Bossers A, Ironside J, Will RG, Chen SG, Petersen RB, Gambetti P, Rubenstein R, Smits MA, Lansbury Jr PT, Caughey B 1997 Molecular assessment of the transmissibilities of BSE and scrapie to humans. Nature 388:285-288
223. Horwitz J, Bova MP, Ding LL, Haley DA, Stewart PL 1999 Lens α-crystallin: function and structure. Eye 13:403-408
224. Dasgupta S, Hohman TC, Carper D 1992 Hypertonic stress induces α B-crystallin expression. Exp Eye Res 54:461-470
225. Aoyama A, Frohli E, Schafer R, Klemenz R 1993 α B-crystallin expression in mouse NIH 3T3 fibroblasts: glucocorticoid responsiveness and involvement in thermal protection Mol Cell Biol 13:1824-1835
226. Mehlen P, Schulze-Osthoff K, Arrigo AP 1996 Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. J Biol Chem 271:16510-16514
227. Horwitz J 1992 α-Crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 89:10449-10453
228. Rao PV, Huang Q-L, Horwitz J, Zigler JS 1995 Evidence that α-crystallin prevents non-specific protein aggregation in the intact eye lens. Biochim Biophys Acta 1245:439-447
229. Renkawek K, Voorter CEM, Bosman GJCGM, van Workim FPA, de Jong WW 1994 Expression of α B-crystallin in Alzheimer's disease. Acta Neuropathol 87:155-160
230. Lowe J, Landon M, Pike I, Spendlove I, McDermott H, Mayer RJ 1990 Dementia with β-amyloid deposition: involvement of α B-crystallin supports two main diseases. Lancet 336:515-516
231. Renkawek K, de Jong WW, Merck KB, Frenken CWGM, van Workim FPA, Bosman GJCGM 1992 α B-crystallin is present in reactive glia in Creutzfeldt-Jakob disease. Acta Neuropathol 83:324-327
232. Head MW, Corbin E, Goldman JE 1993 Overexpression and abnormal modification of the stress proteins α B-crystallin and HSP27 in Alexander disease. Am J Pathol 143:1743-1753
233. Vicart P, Caron A, Guicheney P, Li A, Prevost M-C, Faure A, Chateau D, Chapon F, Tome F, Dupret JM, Paulin D, Fardeau M 1998 A missense mutation in the αB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 20:92-95
234. Bova MP, Yaron O, Huang Q, Ding L, Haley DA, Stewart PL, Horwitz J 1999 Mutation R120G in αB-crystallin, which is linked to a desmin-related myopathy, results in an irregular structure and defective chaperone-like function. Proc Natl Acad Sci USA 96:6137-6142
235. Burrows JAJ, Willis LK, Perlmutter DH 2000 Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. Proc Natl Acad Sci USA 97:1796-1801
236. Teckman J, Qu D, Perlmutter DH 1996 Molecular pathogenesis of liver disease in α1-antitrypsin deficiency. Hepatology 24:1504-1516
237. Marcus NY, Perlmutter DH 2000 Glucosidase and mannosidase inhibitors mediate increased secretion of mutant α1 antitrypsin Z. J Biol Chem 275:1987-1992
238. Morello JP, Salahpour A, Laperrièr A, Bernier V, Arthus MF, Lonergan M, Petäjä-Repo U, Angers S, Morin D, Bichet DG, Bouvier M 2000 Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105:887-895
239. Friedler A, DeDecker BS, Freund SMV, Rüdiger CBS, Fersht AR 2003 Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation." J Mol Biol 336:187-196
240. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli R, Kascsak R, Mendez E, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B 2000 Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355:192-197
241. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, Soto C 2002 Reduction of amyloid load and cerebral damage in a transgenic animal model of Alzheimer's disease by treatment with a b-sheet breaker peptide. FASEB J 16:860-862
242. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P, Diegoli M, Trizio D, Ballinari D 1995 Interaction of the anthracycline 4′-yodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of fibrilogenesis. Proc Natl Acad Sci USA 92:2959-2963
243. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M 2001 Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487:404-407
244. Findels MA 2002 Peptide inhibitors of β amyloid aggregation. Curr Top Med Chem 2:417-423
245. Kelly JW, Balch WE 2003 Amyloid as a natural product. J Cell Biol 161:461-462
246. Jarrett JT, Berger EP, Lansbury Jr PT 1993 The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697
247. Haass C, De Strooper B 1999 The presenilins in Alzheimer's disease-proteolysis holds the key. Science 286:916-919
248. Cohen FE, Kelly JW 2003 Therapeutic approaches to protein-misfolding diseases. Nature 426:905-909
249. Spooner ET, Desal RV, Mori C, Leverone JF, Lemere CA 2002 The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine 21:290-297
250. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO 2003 Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9:448-452
251. Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lutz R, Schugardt N, Lehrach H, Wanker EE 2000 Inhibition of Huntington fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci USA 97:6739-6744
252. Wellington CL, Hayden MR 1997 Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Curr Opin Neurol 10:291-298
253. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR 2000 Inhibiting caspase cleavage of Huntington reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 275:19831-19838
254. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM 2000 Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801
255. Korth C, May BCH, Cohen FE, Prusiner SB 2001 Acridine and phenothiazine derivatives as pharmacotherapeutics for prion diseases. Proc Natl Acad Sci USA 98:9836-9841
256. May BCH, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, Cohen FE 2003 Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 100:3416-3421
257. Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, Zahn R 2003 Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 46:3563-3564
258. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA, Burton DR, Prusiner SB 2001 Antibodies inhibit prion propagation and clear cell culture of prion infectivity. Nature 412:739-743
259. Blass JP 2001 Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 66:851-856
260. Nourhashemi F, Gillette-Guyonnet S, Andrieu S, Ghisolfi A, Ousset PJ, Grandjean H, Grand A, Pous J, Vellas B, Albarede JL 2000 Alzheimer disease: protective factors. Am J Clin Nutr 71:643S-649S
261. Grundman M 2000 Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 71:630S-636S
262. Hughes RE, Olson JM 2001 Therapeutic opportunities in polyglutamine disease. Nat Med 7:419-423
263. Perlmutter DH 2000 Liver injury in α1-antitrypsin deficiency. Clin Liver Dis 4:387-408
264. Ulloa_Aguirre A, Brothers S, Janovick J, Conn PM 2004 Pharmacological rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5:821-837